Table 2.

Renal parameters of the two study modelsa

Renal Mass (g/m2)Glomerular Volume (mm3 × 106)Proximal Tubular Diameter (μm)GFR (ml/min per m2)ERPF (ml/min per m2)Na Excretion (mmol/d)AER (mg/d)
4-wk AGE infusion
    sham47.4 ± 0.60.8 ± 0.146 ± 162 ± 3242 ± 231.2 ± 0.10.5 ± 0.1
    RSA47.6 ± 0.60.9 ± 0.147 ± 160 ± 2236 ± 221.1 ± 0.10.5 ± 0.1
    AGE-RSA49.8 ± 0.9b1.2 ± 0.1b52 ± 1b55 ± 2b158 ± 13b0.8 ± 0.1b0.6 ± 0.1
    AGE-RSA + valsartan47.0 ± 0.8c0.9 ± 0.1c48 ± 1c60 ± 1d160 ± 9b1.7 ± 0.1b,c0.5 ± 0.1
2-wk Ang II infusion
    vehicle48.4 ± 1.00.8 ± 0.146 ± 175 ± 2255 ± 91.3 ± 0.10.3 ± 0.1
    Ang II55.5 ± 1.7b0.9 ± 0.155 ± 2b77 ± 2182 ± 9b2.1 ± 0.22.6 ± 0.6b
    Ang II + pyridoxamine46.8 ± 0.8b,d0.9 ± 0.148 ± 1c75 ± 2171 ± 13b1.4 ± 0.2b,d2.8 ± 0.5b
  • a Data are shown as mean ± SEM. ERPF, effective renal plasma flow; AER, albumin excretion rate.

    P < 0.05

  • b versus model control,

  • c versus AGE-RSA,

  • d versus Ang II.